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Effects of Transcutaneous Electrical Nerve
Stimulation (TENS) on Self-Efficacy and Mood
in Elderly with Mild Cognitive Impairment
Marijn W. Luijpen, Dick F. Swaab, Joseph A. Sergeant, and Erik J. A. Scherder
In previous studies, transcutaneous electrical nerve
stimulation (TENS) has been applied to patients with
either Alzheimer’s disease (AD) or incipient dementia,
resulting in an enhancement in memory and verbal flu-
ency. Moreover, affective behavior was shown to
improve. Based on the positive effects of TENS in AD, it
was hypothesized that TENS would improve self-efficacy
in nondemented elderly with mild cognitive impairment
(MCI) who live in a residential home. Four outcomemea-
sures, that is, a Dutch translation of the General Self-
Efficacy Scale (Algemene Competentie Schaal), the
Groninger Activity Restriction Scale, the Philadelphia
Geriatric Center Morale Scale, and the Geriatric Depres-
sion Scale, were administered. Overall, the results sug-
gest that the experimental group showed a mild improve-
ment in self-efficacy and mood. In contrast, the placebo
group showed a considerable reduction in self-efficacy
and an increase in depression. Limitations of the present
study and suggestions for future research are discussed.
Key Words: Transcutaneous electrical nerve stimulation
(TENS)—Mild cognitive impairment (MCI)—Self-
efficacy—Mood.
Recent reviews indicate that the clinical hall-mark of patients with mild cognitive impair-ment (MCI) is impaired memory in combina-
tion with a preservation of general cognition and
activities of daily life.1,2 This type of MCI has
also been called “amnestic” MCI2 or “single-
domain” MCI3 and is probably caused by degener-
ation of various structures of the medial temporal
lobe such as the hippocampus, the parahippo- cam-
pus, the entorhinal cor-tex, and the perirhinal cor-
tex.4 As opposed to single-domain MCI, patients
with MCI may also show additional impairments in
other cognitive functions, for example, orienta-
tion.5,6 Patients with this type of MCI—called
“multi-domain” MCI—have an even higher risk of
developing probable Alzheimer’s disease (AD) than
those with single-domain MCI.3
Support for multi-domain MCI emerges from the
finding that following the involvement of the
medial temporal lobe,4 the prefrontal cortex is also
involved in MCI.7-9 Indeed, an increased choline
acetyltransferase (ChaT) activity has been ob-
served in both the hippocampus and the frontal
cortex of patients with MCI.10 This finding suggests
a compensatory upregulation of the cholinergic
system. The prefrontal cortex has been associated
with executive functions such as planning, taking
initiatives, and purposeful action/goal-directed
behavior.11 In view of the nature of executive func-
tions, it is logical that they are related to an individ-
ual’s independent functioning. Specifically, execu-
tive functions appear to be a strong predictor for
performance of (instrumental) activities of daily
living.12,13
In addition to a frontal lobe dysfunction as
observed in MCI associated with decline in inde-
pendent functioning, the institutional environ-
ment of a residential home for the elderly might
augment an elderly resident’s decline in inde-
pendent functioning, irrespective of cognitive
impairment. Richardson et al.14 observed that a 1-
year institutionalization caused an increase in
functional limitations and a decrease in activities of
daily living in about one third of the residents.
Indeed, instrumental daily activities such as shop-
ping, preparing meals, and cleaning the room are
not required anymore in a residential home for the
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elderly. Particularly, these latter activities are item-
ized in most activities of daily living (ADL) scales,
rendering them less suitable for the assessment of
independent functioning among institutionally
based elderly. Therefore, as an alternative, the
concept of self-efficacy was used as an outcome
measure in the present study. Self-efficacy refers to
the way the person perceives her or his own inde-
pendent functioning in daily life.15 Replacing inde-
pendent functioning with self-efficacy is justified
in that executive functions are involved in certain
aspects of self-efficacy such as self-regulation.16
The question arises whether frontal lobe func-
tioning, as measured by the patient’s self-efficacy,
could be enhanced. Interestingly, certain types of
peripheral electrical nerve stimulation appeared to
be effective in stimulating areas of the prefrontal
cortex and its functions. For example, in an fMRI-
study, transcutaneous electrical nerve stimulation
(TENS) applied to the right median nerve activated
the anterior cingulate cortex, a frontal area also
involved in executive functions.17 The effects of
TENS, applied to the back at the level of the 1st
thoracic vertebra, have also been examined in AD
patients18-20 and elderly with mild forgetfulness.21
In these studies, executive functions represented
by verbal fluency were found to improve, and
depressive symptoms declined. This latter finding
is important for the present study, in that a strong
relation has been observed between self-efficacy
and depression in other patients such as those with
asthma.22
The rationale underlying the application of
TENS relates to the observat ion that the
neuropathological hallmark of MCI is brain atro-
phy, not cell death.23-25 Shrunken cells characterize
brain atrophy but are still able to respond to
neuronal stimulation as reflected in an increase in
metabolism.23-25 TENS is a type of neuronal stimu-
lation and could increase cortical activity by acti-
vating the locus coeruleus and dorsal raphe
nucleus. These 2 brain stem areas are the sources
of the noradrenergic and serotonergic neurotrans-
mitter systems, and they appear to play an impor-
tant role in the ascending reticular activating sys-
tem (ARAS),26 which has strong connections with
the prefrontal cortex.27
Thus far, the positive effects of TENS on execu-
tive functions and depression have been observed
in patients with mild forgetfulness and AD. TENS
has not been applied to patients with MCI. Because
executive functions and depression are strongly
related to independent functioning/self-efficacy, it
was hypothesized in the present study that TENS
could improve self-efficacy and depression in
patients with MCI who live in a residential home
for the elderly.
METHODS
Participants
A sample of 34 patients with MCI was drawn
from a larger population of 500 institutionally
based elderly. In a preliminary recruitment proce-
dure, participants and nursing staff were informed
about the purpose and nature of the study. Patients
who agreed to participate in the study gave their
informed consent. Over an 18-month study period,
the participants were randomly assigned into 2
groups, that is, an experimental group (n = 17) and
a placebo group (n = 17), by an independent
investigator.
Demographic characteristics. The experimental
group included 2 males and 15 females. The pla-
cebo group consisted of 6 males and 11 females.
The difference in gender between both groups
was not significant (Fisher’s Exact: P = ns). The
experimental and placebo group did not differ
significantly in age (mean = 88.06, range: 79-96, and
mean = 87.35, range: 76-98, respectively; t[32] =
.42; P = 0.68). The level of education was measured
with a 7-point scale: 1) uncompleted elementary
school; 2) completed 6 grades of elementary
school; 3) completed 8 grades of elementary
school; 4) completed 3 years of lower general sec-
ondary education; 5) completed 4 years of lower
general secondary education; 6) preuniversity
education, technical college, higher vocational
education; 7) university. The mean level of educa-
tion of the experimental group showed no signifi-
cant difference compared to the placebo group
(mean = 3.29, range = 2-6, and mean = 3.13, range =
1-6, respectively; t[28] = .28; P = 0.78). The Mini-
Mental State Examination (MMSE)28 was used as an
initial cognitive screening instrument. Both groups
differed significantly in mean MMSE score (see
Table 1 for mean scores, standard deviation,
norms, and group comparison). In view of the very
old group of elderly included in this study, concur-
rent decline in other cognitive domains (e.g.,
attention) could not be avoided and is expressed
in a relatively low overall MMSE score (mean =
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21.82; SD = 3.45). Corrected for age, this score is
still representative of an MCI population, that is,
between the 25th and 50th percentile.29
Cognitive functioning. Patients were screened
using the 5 criteria for the diagnosis “MCI” estab-
lished by Petersen et al.30 as guidelines: 1) in an ini-
tial clinical interview, the patient herself or him-
self, supported by the opinion of the personal
nursing assistant, noticed mild forgetfulness; 2) the
reported decline in memory was objectively
assessed by the memory items of the MMSE and
neuropsychological tests; 3) largely unimpaired
general cognitive functioning as reported by the
participant himself or herself, the nursing staff, the
MMSE, and neuropsychological test scores; 4) the
activities of daily living appeared to be normal; 5)
consulting the medical and nursing staff and
reviewing participant’s medical records revealed
no signs of dementia. Patients were excluded from
participation if they met the NINCDS-ADRDA crite-
ria for probable AD31 and if medical records
showed a history of psychiatric disorder, alcohol-
ism, cerebral trauma, cerebrovascular disease,
hydrocephalus, neoplasm, epilepsy, disturbances
of consciousness, or focal brain disorders.
A short neuropsychological test battery was
administered to measure cognitive functioning
more thoroughly (see Table 1 for means, standard
deviations, norms, and group comparison). The
Digit Span from the Wechsler Memory Scale–
Revised (WMS-R)32 assesses participants’ verbal
short-term memory abilities. The test consists of a
Forward condition, in which participants were
asked to replicate sequences of spoken digits, and
a Backward condition, in which the sequences
were repeated in reverse order. Episodic memory
was measured with the California Verbal Learning
and Memory Test,33 Dutch-version: the Verbal
Learning and Memory Test (VLMT): List A.34 The
VLMT contains 3 subtests, that is: Direct Recall,
participants were invited to recall as many items as
possible from a shopping list (containing 16 items)
that was presented for 5 times; Delayed Recall, par-
ticipants were asked to recall as many items as pos-
sible from the previously trained shopping list
after a 15-min filled interval; and Recognition, par-
ticipants were asked to recognize items of the pre-
viously presented shopping list from an orally pre-
sented list of 44 words. Frontal executive
functioning was measured with 2 tests: Category
Naming35 and Trailmaking version A.36 In the 1st
test, which measures the ability to retrieve infor-
mation from semantic memory, participants were
asked to name as many words belonging to a par-
ticular category in 1 min, that is, an Animal word
category and a Occupational word category. The
2nd test, Trailmaking version A, is a paper-and-
pencil test in which participants are required to
connect numbers on a paper in the correct order as
quickly as possible, and this involves visual
scanning, speed, and attention.
Taken together, with respect to cognition, low-
est scores were observed for attention (Digit Span
Forward condition, Trailmaking A), working mem-
ory (Digit Span Backward Condition), and short-
and long-term retrieval from memory (VLMT
Direct Recall and Delayed Recall). These findings
further support the diagnosis of MCI.
MATERIAL AND PROCEDURE
To evaluate the effects of TENS on self-efficacy
and depression, the following scales were admin-
istered and used as outcome measures.
Self-Efficacy
Algemene Competentie Schaal (ALCOS)37 is a
Dutch translation of the General Self-Efficacy
Scale.38 The ALCOS is a 5-point scale that consists
of 3 subscales: 1) Competence (4 items), 2) Perse-
verance When Experiencing Adversity (5 items),
and 3) Taking Initiatives (3 items). A higher score is
indicative for more self-efficacy. The maximum
score is 60. The test-retest reliability of the ALCOS
appears to be adequate (r = 0.84), whereas the
internal consistency varies from Cronbach’s α =
0.86 for the test to Cronbach’s α = 0.89 for the
retest.39 Another study that included 144 elderly
with an age ranging from 55 to 90 years reported
an internal consistency of Cronbach’s α = 0.87.40
The Groninger Activity Restriction Scale
(GARS)41,42 is an 18-item functional status scale.
More specific, each item has a response range from
1 to 4, reflecting an increasing extent of depend-
ency. For example, 1 item refers to the extent of
independent dressing. Item scores range from 1
(completely independent) to 4 (completely
dependent). The lower the score, the less the
impairment of the patient (range in scores: 18-72).
The GARS is not a self-efficacy scale by nature but
a mixed ADL/IADL scale. During instruction of the
scale, we emphasized that it was not important
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Table 1. Overall and Group Mean Memory and Executive Function Test Scores, Standard Deviations, Norms or Maximum Scores, and t Test Group Comparison
Overall Group Experimental Group Placebo Group t Test
Score (N = 34) (n = 17) (n = 17) (Experimental-Placebo)
Tests M SD Population Norms (Age Range) M SD M SD t df P
MMSE 21.82 3.45 25th-50th percentile (89 years) 20.24 3.70 23.41 2.35 2.99 32 0.005
WMS-R digit span
Forward condition 4.82 1.53 6th-12th percentile (70-74 years) 4.44 1.31 5.21 1.67 1.49 32 ns
Backward condition 3.91 1.28 14th-26th percentile (70-74 years) 3.50 1.02 4.32 1.41 1.95 32 ns
VLMT
Direct recall 27.68 11.32 Maximum score: 80 28.79 12.55 26.56 10.21 0.57 32 ns
Delayed recall 2.91 3.49 Maximum score: 16 3.24 4.05 2.59 2.92 0.53 32 ns
Recognition 37.31 4.64 Maximum score: 44 36.91 4.89 37.71 4.50 0.49 32 ns
Category naming
Animal word category 11.40 3.54 T-score 48-50 (89-93 years) 11.65 4.06 11.15 3.02 0.41 32 ns
Occupational
word category 8.37 3.31 T-score 46-48 (85-88 years) 8.41 3.13 8.32 3.58 0.08 32 ns
Trailmaking version A 105.56 44.42 25th percentile (70-79 years) 107.88 30.31 103.09 56.72 0.31 31 ns
MMSE = Mini-Mental State Examination; WMS-R = Wechsler Memory Scale-Revised; VLMT = Verbal Learning and Memory Test; M = mean; SD = standard deviation; ns = not significant.
whether the requested activity (e.g., doing heavy
domestic labor or cleaning the bed) was still
appropriate for the setting they were in. The man-
ual of the GARS evaluates the test-retest reliability
and internal consistency obtained from several
studies in the Netherlands.43 The test-retest relia-
bility coefficient ranged from r = 0.53 (P < 0.1) to
r = 0.74 (P < 0.1), whereas the internal consistency
varied between Cronbach’s α = 0.83 and
Cronbach’s α = 0.94.
The Philadelphia Geriatric Center Morale Scale
(PGCMS)44,45 is a 17-item battery that consists of 3
subscales: 1) Agitation (8 items), 2) Attitude
toward Aging (6 items), and 3) Dissatisfaction (4
items). Sixteen items have only 2 dichotomous
response categories, that is, yes-no, often–not
often, and not satisfied–satisfied. One item
includes a statement in which the participant is
asked to fill in 1 of the following words: better,
worse, the same. The total score is 18. A higher
score indicates better morale. In a study that
included 1086 elderly, Lawton44 found an internal
consistency of Cronbach’s α = 0.85 for the subscale
Agitation; Cronbach’s α = 0.81 for Attitude toward
Aging; and Cronbach’s α = 0.85 for Dissatisfaction.
The test-retest reliability found in a study that
administered the Dutch translation of the PGCMS
was r = 0.82 (P < 0.0001).46
Depressive Symptoms
The Geriatric Depression Scale (GDS)47,48 is a
valid and reliable self-rating scale,49 which has
been developed for application in an elderly pop-
ulation and which is also suitable for the assess-
ment of treatment effects.50 Laprise and Vézina51
reported an adequate test-retest correlation coeffi-
cient of 0.70 (P < 0.0001). The GDS consists of 30
items with no or yes responses (maximum score:
30). A score equal to or greater than 11 indicates
depression, whereas a score of 10 or less indicates
the absence of depression.47,48 However, a cutoff
score of 14 has higher agreement with a “clinical
diagnosis of depression.”51
Stimulation
The TENS signal is thought to (re)activate corti-
cal brain regions involved in cognitive functioning
through afferent peripheral nerve fibers of the
somatosensory system. This hypothesis is based
on animal experimental studies, which reported an
increase in hippocampal and hypothalamic activ-
ity, possibly mediated through supraspinal areas,
as a result of tactile and electrical stimulation of the
somatosensory system.52-54 An activation of
supraspinal areas, for example, the dorsal raphe
nucleus, the locus coeruleus, and subsequently
the prefrontal cortex, by TENS might be transmit-
ted by afferent nerve fibers, that is, thick-
myelinated A-Beta fibers, thin-myelinated A-Delta
fibers, and un- myelinated C fibers.55,56 The condi-
tions (stimulation- parameters) under which these
3 types of afferent nerve fibers in patients with MCI
could be optimally stimulated originate from ani-
mal studies dealing with analgesia.57-64
Frequency and intensity. A-Beta fibers respond
very well to both high- (e.g., 100 Hz) and low-fre-
quency stimulation (e.g., 2 Hz).57,58,60 A-Delta and C
fibers preferably respond to low-frequency stimu-
lation (less than 10 Hz) with a nonpainful intensity
that triggers strong muscular contractions.61-65
To activate all 3 types of afferent nerve fibers,
high-frequency and low-frequency stimulation
had to be combined in 1 treatment. Therefore,
TENS characterized by asymmetric biphasic
square impulses was applied in bursts of trains, 9
pulses per train, with an internal frequency of
160 Hz, a repetition rate of 2 Hz, and a pulse width
of 100 µsec. This type of TENS is known as BURST-
TENS.66 Importantly, a burst signal is most
appropriate to stimulate the prefrontal cortex.67 The
intensity of the stimulation was high enough to pro-
voke muscular twitches, which were painless.
Participants in the experimental group were
treated with an electrostimulator, type Premier 10s.
The same electrostimulator was applied to partici-
pants of the placebo group. However, no current
was administered to the patients (sham stimula-
tion). To avoid possible effects resulting from this
difference, each participant was informed that the
perceptibility for the TENS signal varies for each
individual. Both groups were told that the TENS
signal was applied as soon as a green LED on the
electrostimulator began to flash.
Location. The participant was sitting in a chair.
Two 2 × 3 cm self-adhesive standard carbon rubber
electrodes with gel were fixed on the participant’s
back, between the 1st and 5th thoracic level on
each side of the spinal column.
Treatment time and period. Participants were
treated 30 min a day, 5 days a week, for 6 consecu-
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tive weeks. These parameters are based on earlier
TENS studies, which reported enhancement in
cognitive and behavioral functioning in both
demented and nondemented elderly applying this
treatment duration and period.19,21
Measurement Moments
The self-efficacy scales and the depression scale
(GDS) were applied at 4 points, that is, 6 weeks be-
fore the TENS treatment started (pretreatment 1:
T1), just before the onset of the 6-week treatment
period (pretreatment 2: T2), directly after the 6
weeks of treatment (post: T3), and again after a 6-
week treatment- free period (delayed: T4). An inde-
pendent investigator, unaware of the group iden-
tity of participants, administered the scales.
Statistical Analyses
First, it was calculated whether the pretreatment
measurement scores (T1 and T2) of each scale
could be pooled to reduce within-subjects variabil-
i ty . This procedure resul t s in a gain of
discriminative power and is appropriate when the
pretreatment scores do not differ significantly.
Next, to answer the main question of the investi-
gation, Does TENS treatment improve self-efficacy
and mood? each self-efficacy and mood (sub)scale
was submitted to a 1-way analysis of covariance
(ANCOVA) with group (2 levels: experimental and
placebo) as independent variable, the posttreat-
ment score (T3) as dependent variable, and, if ap-
propriate, the pooled pretreatment baseline score
(T(1,2)) as covariate. If an ANCOVA revealed a sig-
nificant group effect for an outcome measure, post
hoc single-tailed paired-samples t tests at a 0.05
significance level were performed to evaluate dif-
ferences within the experimental and placebo
group.
Furthermore, although an independent-sam-
ples t test did show a significant group difference
in MMSE score (see Methods, subsection Partici-
pants), it was calculated whether the MMSE score
should be included in the analysis as a 2nd
covariate. For this purpose, each self-efficacy or
mood (sub)scale was submitted to an ANCOVA—
with group as independent variable (2 levels:
experimental and placebo), the posttreatment
score (T3) as dependent variable, and both the
MMSE score and the pooled pretreatment score
(T(1,2)) as covariates. The SPSS-PC program was
applied for data analyses.68
RESULTS
A preliminary series of paired-samples t tests
showed no significant differences between the
pretreatment scores (T1 and T2) of the experimen-
tal group and placebo group for each self-efficacy
and mood (sub)scale. Therefore, it was justified to
pool both pretreatment scores (T(1,2)). Subse-
quently, an ANCOVA with group as independent
variable (2 levels: experimental and placebo), the
posttreatment score (T3) as dependent variable,
and both the MMSE score and the pooled pretreat-
ment score (T(1,2)) as covariates showed that the
MMSE scores did not have a significant influence
on the self-efficacy and mood (sub)scale scores.
Consequently, the MMSE scores were not included
as a covariate in further analyses.
Algemene Competentie
Schaal (ALCOS)
The results of the ANCOVA (Group [experimen-
tal, placebo] × Measurement moment [T3]) (see
Table 2) showed a significant main effect for group
for the ALCOS scores. This effect is explained by a
significant decrease in scores within the placebo
group as indicated by post hoc paired-samples t
tests (t[16] = 1.74, P = 0.05). A lower score implies a
decline in self-efficacy. The slight increase in
scores within the experimental group was not sig-
nificant (t[16] = .43, P = 0.34). The ANCOVA per-
formed on the 3 subscales, that is, Competence,
Perseverance When Experiencing Adversity, and
Taking Initiatives, revealed a significant main
effect for group for the ALCOS subscale Taking Ini-
tiatives. Paired-samples t tests showed a significant
decline on this subscale within the placebo group
(t[16] = 2.13, P < 0.03), whereas the change in score
within the experimental group over time was not
significant (t[16] = .65, P < 0.27).
Groninger Activity Restriction
Scale (GARS)
The 1-way ANCOVA (Group [experimental, pla-
cebo] × Measurement moment [T3]) conducted on
the GARS scores revealed a significant main effect
for group (see Table 2). Post hoc paired-samples t
tests indicated a nonsignificant decrease in score
(improvement in self-efficacy) within the experi-
mental group (t[16] = 1.35, P < 0.10) and an
increase in score (decline in self-efficacy) within
the placebo group (t[16] = 1.49, P < 0.08).
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Table 2. Means, Standard Deviations, and Analyses of Covariance of the Self-Efficacy and Depression Scales
Experimental Group Placebo Group
Pretreatment Posttreatment Delayed Pretreatment Posttreatment
Pooled (T1,2) (T3) (T4) Pooled (T1,2) (T3) Delayed (T4) ANCOVA Pre-Post
Self-Efficacy and Mood Scales M SD M SD M SD M SD M SD M SD F df P
GDS 7.94 3.25 7.35 3.22 7.00 4.63 10.35 5.68 11.82 6.79 9.25 4.93 4.35 1,31 0.02
GARS 40.65 9.32 39.35 10.14 39.37 10.46 44.00 13.31 45.41 13.71 45.31 13.31 3.90 1,31 0.03
ALCOS (overall) 40.18 4.81 40.65 6.59 41.63 4.90 39.35 6.84 36.71 7.42 39.00 5.77 3.17 1,31 0.04
Subscales
Competence 12.79 2.91 12.88 3.87 13.56 3.29 12.15 4.07 11.82 4.38 12.13 4.30 0.27 1,31 0.30
Perseverance when
experiencing adversity 20.88 3.31 20.88 3.33 22.00 2.73 20.82 3.21 20.35 3.12 20.81 3.15 0.29 1,31 0.29
Taking initiatives 6.50 2.30 6.88 3.26 6.06 2.44 6.38 2.00 5.12 2.57 6.06 2.35 4.04 1,31 0.03
PGCMS (overall) 11.85 2.85 11.94 3.96 11.56 3.39 9.65 4.59 9.35 5.24 10.06 4.30 0.23 1,31 0.64
Subscales
Agitation 5.32 1.79 5.65 1.58 5.38 2.58 4.74 2.73 4.71 2.89 4.94 2.52 1.11 1,31 0.15
Attitude toward aging 3.00 1.06 3.24 1.68 2.75 1.39 2.15 1.34 2.06 1.68 2.19 1.68 1.02 1,31 0.16
Dissatisfaction 3.53 0.45 3.29 0.77 3.44 1.03 2.76 1.17 2.59 1.42 2.94 1.06 0.01 1,31 0.46
GDS = The Geriatric Depression Scale; GARS = The Groninger Activity Restriction Scale; ALCOS = Algemene Competentie Schaal; PGCMS = The Philadelphia Geriatric Center Morale Scale;
M = mean; SD = standard deviation.
Philadelphia Geriatric Center
Morale Scale (PGCMS)
The ANCOVA (Group [experimental, placebo] ×
Measurement moment [T3]) performed on the
PGCMS revealed no significant main effect for
group (see Table 2). As a result, no additional
paired- samples t tests were conducted. ANCOVA
of the 3 subscales, that is, Agitation, Attitude
toward Aging, and Dissatisfaction, showed no sig-
nificant main effects for group.
Geriatric Depression Scale (GDS)
ANCOVA (Group [experimental, placebo] ×
Mea- surement moment [T3]) indicated a signifi-
cant main effect for group for the GDS scores (see
Table 2). Specifically, the scores of the experimen-
tal group on the GDS became smaller, whereas the
scores of the placebo group increased. Paired sam-
ples t tests showed that the GDS score increased
significantly within the placebo group (t[16] = 2.14;
P < 0.03), whereas the decrease in GDS score
within the experimental group did not reach signif-
icance (t[16] = .86; P < 0.20).
DISCUSSION
The main finding in the present study was the
absence of a statistically significant beneficial
effect of TENS treatment on self-efficacy and mood
in an MCI population. More specific, the experi-
mental group showed hardly any change on the
questionnaires, whereas self-efficacy and mood
within the placebo group declined. This decline
was statistically significant for the ALCOS overall
score and its subscale Taking Initiatives, and the
GDS score, whereas the GARS score declined
nonsignificantly. The decline in self-efficacy and
mood observed within the placebo group was rela-
tively stronger than the enhancement found in the
experimental group, and therefore primarily
responsible for the significant main effects for
group observed in the ANCOVA of the GDS, and
the ALCOS overall and its subscale Taking Initia-
tives. The only scale that did not show a significant
main effect for group was the PGCMS. A possible
explanation might be that compared to the other
scales, this scale has a limited number of items and
dichotomous response categories.
The question that arises from the present find-
ings is 2-fold: 1st, why did not TENS improve self-
efficacy and mood in the experimental group? and
2nd, why did the placebo group show a decline in
self-efficacy and mood during the treatment
period?
With respect to the 1st question, one of the
major risk factors for MCI is the presence of the
apolipoprotein E ε4 allele (APOE ε4).69 In AD,
APOE ε4 is associated with a reduction in regional
cerebral metabolic rate of glucose in, among oth-
ers, the prefrontal regions.70 Importantly, although
findings are equivocal, APOE ε4 may decrease the
effectiveness of specific types of interventions
such as tacrine, a cholinesterase inhibitor, and
estrogen in AD.71,72 The possibility that APOE ε4
also hinders the effectiveness of TENS in an MCI
population should be examined in future research.
With respect to the 2nd question, the decline in
self-efficacy and mood in the placebo group might
be explained by the so-called nocebo reaction,
that is, the opposite of a placebo reaction.73-76 The
nocebo reaction might, as the placebo effect,
involve 2 possible underlying mechanisms: condi-
tioning and cognitive factors.77,78 With regard to
conditioning, context and environment (e.g., color
of pills, instruments used for the treatment, hospi-
tal setting) represent the conditioned stimulus, and
the associated valence of these cues may cause a
placebo or nocebo response. More specific, the
application of electrical current and electrodes in
the present study may have been perceived as con-
ditioned stimuli with a negative valence and trig-
ger a nocebo response. This response is reflected
in a substantial decline in self-efficacy and mood in
the placebo group. In the experimental group, the
nocebo reaction may have been counteracted by
the positive influence of the TENS treatment.
Cognitive processes (e.g., expectations, beliefs)
may also play a role in the nature of the response,
that is, placebo or nocebo. We hypothesize that
unmet expectations might have played a role in
inducing a nocebo effect. Participating in the study
required high commitment from the participants—
the treatment was applied 30 min a day, 5 days a
week, for 6 consecutive weeks—and the lack of
experiencing any beneficial effects as a result of
the sham treatment might have triggered a nocebo
response.
Taken together, a suggestion for future TENS
research is to control for the presence of the APOE
ε4 allele and examine possible differences in effi-
cacy of the treatment related to the presence or
absence of this specific genotype. Considering the
previous discussed factors that might cause a
nocebo reaction, future TENS research should
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include a short questionnaire in which participants
are asked how they experienced the application of
electrodes, the use of electrical current, and the
daily visits of the investigator. Another proposal is
to assess expectations regarding TENS treatment
with a questionnaire asking whether those expec-
tations are met after cessation of the treatment.
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